ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.92018
-0.37%
Brent Oil
83.59
0.56%
Bitcoin
64,067.94
0.11%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Noticias

NUVL Nuvalent Inc

70.35
0.00 (0.00%)
Pre Mercado
Última actualización: 05:37:29
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Nuvalent Inc NUVL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 70.35 05:37:29
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
70.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202415:30PRNUSNuvalent Presents New Preclinical Data Supporting Profiles..
05/3/202415:52PRNUSNuvalent to Present New Preclinical Data on HER2-Selective..
27/2/202406:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202405:42EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202405:38EDGAR2Form 8-K - Current report
27/2/202405:30PRNUSNuvalent Highlights Pipeline Progress, Reiterates Key..
27/2/202405:15PRNUSNuvalent Receives U.S. FDA Breakthrough Therapy Designation..
12/2/202405:30PRNUSNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical..
01/2/202405:30PRNUSNuvalent to Participate in the Guggenheim Healthcare Talks..
09/1/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:40EDGAR2Form 8-K - Current report
08/1/202405:30PRNUSNuvalent Announces "OnTarget 2026" Operating Plan and Key..
28/12/202316:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202315:31EDGAR2Form 144 - Report of proposed sale of securities
21/12/202305:30PRNUSNuvalent to Present at the 42nd Annual J.P. Morgan..
20/12/202315:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202317:00EDGAR2Form 144 - Report of proposed sale of securities
18/12/202316:45EDGAR2Form 144 - Report of proposed sale of securities
18/12/202316:32EDGAR2Form 144 - Report of proposed sale of securities
18/12/202316:23EDGAR2Form 144 - Report of proposed sale of securities
30/11/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202305:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202305:45EDGAR2Form 8-K - Current report
14/11/202305:30PRNUSNuvalent Highlights Corporate and Pipeline Achievements and..
03/11/202315:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202305:30PRNUSNuvalent to Participate in the BMO Virtual BioPharma..
26/10/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202317:01EDGAR2Form 144 - Report of proposed sale of securities
17/10/202315:07EDGAR2Form 8-K - Current report
17/10/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/10/202320:55PRNUSNuvalent Announces Pricing of Public Offering of Common..
16/10/202306:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/10/202306:30PRNUSNuvalent Announces Public Offering of Common Stock
13/10/202305:40EDGAR2Form 8-K - Current report
13/10/202305:30PRNUSNuvalent Reports Preliminary Phase 1 Clinical Data from..
06/10/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202315:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202315:12EDGAR2Form 144 - Report of proposed sale of securities
04/10/202315:05EDGAR2Form 8-K - Current report
04/10/202311:21PRNUSPreliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial..
19/9/202315:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202305:30PRNUSNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2..
06/9/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
NUVL
Nuvalent
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados